T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia

Andrea Bacigalupo, Marisa Valle, Marina Podestà, Anna Pitto, Elena Zocchi, Antonio De Flora, Sara Pozzi, Silvia Luchetti, Francesco Frassoni, Maria Teresa Van Lint, Giovanna Piaggio

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Objective. To compare the suppressive effect of mesenchymal stem cells (MSC), derived from normal individuals or severe aplastic anemia patients (SAA), on T-cell activation. Patients and Methods. We studied bone marrow MSC from 19 healthy donors and 23 SAA patients in different phases of the disease: at diagnosis (n = 3), following immunosuppressive therapy (IS) (n = 16), or after a bone marrow transplant (BMT) (n = 4). MSC were tested for T-cell suppression in the following assays: mixed lymphocyte reaction (MLR), phytohemaglutinin (PHA)-primed cultures, activation surface markers, γ-IFN production, hematopoietic colony formation (CFC), production of cyclic ADP-ribose (cADPR). Results. The abnormalities of SAA MSC included: 1) significantly lower suppression of T-cell proliferation induced by alloantigens (p = 0.009) or PHA (p = 0.006); 2) impaired capacity to suppress CD38 expression on PHA-primed T cells (p = 0.001); 3) impaired ability to suppress γ-IFN production in PHA cultures, resulting in an 11-fold higher γ-IFN concentration; 4) no preventive effect on T cell-mediated inhibition of CFC; and 5) significantly reduced (p = 0.009) production of cADPR, a universal calcium mobilizer. MSC-mediated suppression of PHA-induced T-cell proliferation was restored to control levels in 3 of 4 patients post-BMT. Conclusion. The ability of MSC to downregulate T-cell priming, proliferation, and cytokine release is deficient in patients with SAA, persists indefinitely after immunosuppressive therapy, but seems to be restored after BMT. Whether these abnormalities are relevant to the pathogenesis of aplastic anemia remains to be determined.

Original languageEnglish
Pages (from-to)819-827
Number of pages9
JournalExperimental Hematology
Volume33
Issue number7
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Aplastic Anemia
Mesenchymal Stromal Cells
T-Lymphocytes
Bone Marrow
Cyclic ADP-Ribose
Cell Proliferation
Immunosuppressive Agents
Transplants
Mixed Lymphocyte Culture Test
Isoantigens
Down-Regulation
Tissue Donors
Cytokines
Calcium
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. / Bacigalupo, Andrea; Valle, Marisa; Podestà, Marina; Pitto, Anna; Zocchi, Elena; De Flora, Antonio; Pozzi, Sara; Luchetti, Silvia; Frassoni, Francesco; Van Lint, Maria Teresa; Piaggio, Giovanna.

In: Experimental Hematology, Vol. 33, No. 7, 07.2005, p. 819-827.

Research output: Contribution to journalArticle

Bacigalupo, Andrea ; Valle, Marisa ; Podestà, Marina ; Pitto, Anna ; Zocchi, Elena ; De Flora, Antonio ; Pozzi, Sara ; Luchetti, Silvia ; Frassoni, Francesco ; Van Lint, Maria Teresa ; Piaggio, Giovanna. / T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. In: Experimental Hematology. 2005 ; Vol. 33, No. 7. pp. 819-827.
@article{7f9f27dbac9d450caaec66922854b9fb,
title = "T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia",
abstract = "Objective. To compare the suppressive effect of mesenchymal stem cells (MSC), derived from normal individuals or severe aplastic anemia patients (SAA), on T-cell activation. Patients and Methods. We studied bone marrow MSC from 19 healthy donors and 23 SAA patients in different phases of the disease: at diagnosis (n = 3), following immunosuppressive therapy (IS) (n = 16), or after a bone marrow transplant (BMT) (n = 4). MSC were tested for T-cell suppression in the following assays: mixed lymphocyte reaction (MLR), phytohemaglutinin (PHA)-primed cultures, activation surface markers, γ-IFN production, hematopoietic colony formation (CFC), production of cyclic ADP-ribose (cADPR). Results. The abnormalities of SAA MSC included: 1) significantly lower suppression of T-cell proliferation induced by alloantigens (p = 0.009) or PHA (p = 0.006); 2) impaired capacity to suppress CD38 expression on PHA-primed T cells (p = 0.001); 3) impaired ability to suppress γ-IFN production in PHA cultures, resulting in an 11-fold higher γ-IFN concentration; 4) no preventive effect on T cell-mediated inhibition of CFC; and 5) significantly reduced (p = 0.009) production of cADPR, a universal calcium mobilizer. MSC-mediated suppression of PHA-induced T-cell proliferation was restored to control levels in 3 of 4 patients post-BMT. Conclusion. The ability of MSC to downregulate T-cell priming, proliferation, and cytokine release is deficient in patients with SAA, persists indefinitely after immunosuppressive therapy, but seems to be restored after BMT. Whether these abnormalities are relevant to the pathogenesis of aplastic anemia remains to be determined.",
author = "Andrea Bacigalupo and Marisa Valle and Marina Podest{\`a} and Anna Pitto and Elena Zocchi and {De Flora}, Antonio and Sara Pozzi and Silvia Luchetti and Francesco Frassoni and {Van Lint}, {Maria Teresa} and Giovanna Piaggio",
year = "2005",
month = "7",
doi = "10.1016/j.exphem.2005.05.006",
language = "English",
volume = "33",
pages = "819--827",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia

AU - Bacigalupo, Andrea

AU - Valle, Marisa

AU - Podestà, Marina

AU - Pitto, Anna

AU - Zocchi, Elena

AU - De Flora, Antonio

AU - Pozzi, Sara

AU - Luchetti, Silvia

AU - Frassoni, Francesco

AU - Van Lint, Maria Teresa

AU - Piaggio, Giovanna

PY - 2005/7

Y1 - 2005/7

N2 - Objective. To compare the suppressive effect of mesenchymal stem cells (MSC), derived from normal individuals or severe aplastic anemia patients (SAA), on T-cell activation. Patients and Methods. We studied bone marrow MSC from 19 healthy donors and 23 SAA patients in different phases of the disease: at diagnosis (n = 3), following immunosuppressive therapy (IS) (n = 16), or after a bone marrow transplant (BMT) (n = 4). MSC were tested for T-cell suppression in the following assays: mixed lymphocyte reaction (MLR), phytohemaglutinin (PHA)-primed cultures, activation surface markers, γ-IFN production, hematopoietic colony formation (CFC), production of cyclic ADP-ribose (cADPR). Results. The abnormalities of SAA MSC included: 1) significantly lower suppression of T-cell proliferation induced by alloantigens (p = 0.009) or PHA (p = 0.006); 2) impaired capacity to suppress CD38 expression on PHA-primed T cells (p = 0.001); 3) impaired ability to suppress γ-IFN production in PHA cultures, resulting in an 11-fold higher γ-IFN concentration; 4) no preventive effect on T cell-mediated inhibition of CFC; and 5) significantly reduced (p = 0.009) production of cADPR, a universal calcium mobilizer. MSC-mediated suppression of PHA-induced T-cell proliferation was restored to control levels in 3 of 4 patients post-BMT. Conclusion. The ability of MSC to downregulate T-cell priming, proliferation, and cytokine release is deficient in patients with SAA, persists indefinitely after immunosuppressive therapy, but seems to be restored after BMT. Whether these abnormalities are relevant to the pathogenesis of aplastic anemia remains to be determined.

AB - Objective. To compare the suppressive effect of mesenchymal stem cells (MSC), derived from normal individuals or severe aplastic anemia patients (SAA), on T-cell activation. Patients and Methods. We studied bone marrow MSC from 19 healthy donors and 23 SAA patients in different phases of the disease: at diagnosis (n = 3), following immunosuppressive therapy (IS) (n = 16), or after a bone marrow transplant (BMT) (n = 4). MSC were tested for T-cell suppression in the following assays: mixed lymphocyte reaction (MLR), phytohemaglutinin (PHA)-primed cultures, activation surface markers, γ-IFN production, hematopoietic colony formation (CFC), production of cyclic ADP-ribose (cADPR). Results. The abnormalities of SAA MSC included: 1) significantly lower suppression of T-cell proliferation induced by alloantigens (p = 0.009) or PHA (p = 0.006); 2) impaired capacity to suppress CD38 expression on PHA-primed T cells (p = 0.001); 3) impaired ability to suppress γ-IFN production in PHA cultures, resulting in an 11-fold higher γ-IFN concentration; 4) no preventive effect on T cell-mediated inhibition of CFC; and 5) significantly reduced (p = 0.009) production of cADPR, a universal calcium mobilizer. MSC-mediated suppression of PHA-induced T-cell proliferation was restored to control levels in 3 of 4 patients post-BMT. Conclusion. The ability of MSC to downregulate T-cell priming, proliferation, and cytokine release is deficient in patients with SAA, persists indefinitely after immunosuppressive therapy, but seems to be restored after BMT. Whether these abnormalities are relevant to the pathogenesis of aplastic anemia remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=20444491475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444491475&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2005.05.006

DO - 10.1016/j.exphem.2005.05.006

M3 - Article

VL - 33

SP - 819

EP - 827

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 7

ER -